102 results about "Hyperlipemias" patented technology

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

The invention provides a lipid-lowering traditional Chinese medicine composition and extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The lipid-lowering traditional Chinese medicine composition is prepared from the following raw materials: rhizoma cyperi and radix gentianae. The invention further provides an extract of the lipid-lowering traditional Chinese medicine composition. The extract is obtained by mixing rhizoma cyperi and radix gentianae and then co-extracting. The composition or the extract can be used for preparing medicines for preventing and / or treating hyperlipemia, and can be used for improving lipid metabolism disorder of liver cells and reducing the content of triglyceride and total cholesterol in the liver cells.

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

This invention relates to extracts of traditional Chinese medicine, and particularly to the application of a compound extract with lipid-regulating effects in the preparation of lipid-regulating drugs. Experimental studies of this invention have found that a compound traditional Chinese medicine lipid-regulating formula, administered for 14 weeks, can effectively reduce serum total cholesterol levels in hyperlipidemic mice. Furthermore, the lipid-lowering effects of the compound formula at 7.08 g / kg (high-dose group) and 3.54 g / kg (low-dose group) in hyperlipidemic mice are similar to those of simvastatin. Moreover, the dosage of the lipid-regulating compound formula is lower. This important compound lipid-regulating formula described in this invention can be applied to the prevention and treatment of hyperlipidemia, providing a new option for the prevention and treatment of hyperlipidemia.

The present invention provides a pharmaceutical composition comprising a) a first phase comprising rosuvastatin, and b) a second phase comprising acetylsalicylic acid, wherein the first phase comprising rosuvastatin is in the form of a coated tablet, and the second phase comprising acetylsalicylic acid is in the form of granules; said pharmaceutical composition solves a set of significant technological challenges due to the physicochemical properties and difference in dosage of each drug. The pharmaceutical composition of the present invention is stable, and also has a comparative bioavailability equivalent to that of the co-administered monodrugs, so that the composition is safe and effective in the treatment of hyperlipidemias and in the prevention of at least one cardiovascular disease. The invention is also directed to a process for manufacturing the pharmaceutical composition.

The application relates to the field of biological medicine, and particularly discloses Creld2 as a biomarker of atherosclerosis. For the first time, the Creld2 level of mouse models of obesity, diabetes, hyperlipidemia and atherosclerosis is detected, and it is found that the serum Creld2 level is greatly increased only when atherosclerosis occurs. The increase of the Creld2 level is related to the development process of atherosclerosis, and with the aggravation of atherosclerotic plaques, the serum Creld2 level is further increased. The serum Creld2 level of the atherosclerosis model group is greatly increased compared with the normal control group, and the Creld2 level ranges of the two groups do not overlap, so that the Creld2 is taken as the biomarker of atherosclerosis and has high diagnostic efficiency, can be used as an early blood diagnostic marker of atherosclerosis, is beneficial to low-cost, large-scale screening and monitoring, can be used for early diagnosis and treatment of atherosclerosis, and improves the life quality of patients.

This invention relates to *Lactobacillus paracasei* NEFU-5 and its applications, belonging to the field of biotechnology. To address the problems of limited functionality and poor direct degradation of metabolites in existing probiotic strains, this invention provides *Lactobacillus paracasei* NEFU-5 (accession number CCTCC NO: M 2026147). This *Lactobacillus paracasei* NEFU-5 can simultaneously and efficiently degrade uric acid, triglycerides, and cholesterol, and possesses excellent probiotic properties and safety. The *Lactobacillus paracasei* NEFU-5 provided by this invention can be used to prepare fermented products and can be used to prevent or improve hyperuricemia, hyperlipidemia, and other concurrent metabolic diseases, showing significant application prospects.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The present invention relates to the method for obtaining in pure form or as a mixture of the bioactive diol forms of the main secoiridoid phenols present in olive oil and certain isomeric forms or derivatives thereof. Specifically, it relates to the production process of S-(E)-oleocanthadiol, S-(E)-oleaceinediol, 5S-(E)-oleomissionadiol, 5S-(E)-oleokoronadiol, oleuropeinediol and ligstrodiol and their corresponding polyethylene glycol hemiacetals through extraction of specifically selected olive oil with polyethylene glycol and then treated with water. It also relates to the pharmaceutical preparations containing the above substances in various combinations and the therapeutic properties of these preparations for the treatment of cancer, degenerative diseases of the central nervous system, diabetes, hyperlipidemia, inflammatory diseases and the prevention of creation of atherosclerotic plaques and thrombi.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

The invention provides compound essential oil of bastardwood and application of the compound essential oil in preparation of products for preventing and treating hyperlipidemia, and relates to the technical field of traditional Chinese medicine essential oil. The traditional Chinese medicine compound essential oil is prepared from radix morindae officinalis essential oil, rhizoma coptidis essential oil and radix aucklandiae essential oil. The traditional Chinese medicine compound essential oil can significantly reduce the weight gain trend of a hyperlipidemia mouse model, reduce the weight of the mouse, effectively reduce the triglyceride, cholesterol and LDL level in serum and liver of the hyperlipidemia mouse model, improve the HDL level, significantly improve the hyperlipidemia symptom of the model mouse, and achieve the purpose of regulating lipid metabolism; meanwhile, liver fatty degeneration can be inhibited, the diameter of fat cells is reduced, and the traditional Chinese medicine compound essential oil has huge application potential in treatment or prevention of hyperlipidemia.

1. Name of the product in this design: Playing cards (Diet for patients with hyperlipidemia and pancreatitis). 2. Purpose of this design: For use in playing card entertainment products. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design highlights: Component 1 main view. 5. The design for which protection is sought includes color. 6. This design is for a thin product, and the left, right, top, and bottom views of components 1 to 54 are omitted.

The application belongs to the technical field of biological medicine, and discloses a novel polypeptide with lipid-lowering effect. In view of the problem that polypeptides are prone to be enzymolyzed in the gastrointestinal tract and difficult to play obvious effect in the body, a novel polypeptide is designed, and the amino acid sequence of the polypeptide is GQAIWMY. The polypeptide GQAIWMY has lipid-lowering capacity, is not prone to be degraded by gastrointestinal enzymes and is more stable, and can be used for preparing drugs for preventing or treating cardiovascular diseases (such as hyperlipidemia, atherosclerosis, coronary heart disease) and fatty liver diseases.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The application discloses 3-substituted coumarin derivatives 1a-14a and symmetrical biscoumarin derivatives 1b-25b and pharmaceutically acceptable salts, solvates or hydrates thereof. The compounds provided by the application are specific inhibitors of ATP citrate lyase (ACLY), and the half maximal inhibitory concentration (IC 50 ) of the former is 2-30 muM, and the IC 50 ) of the latter is 0.065-4 muM, so the compounds have potential therapeutic value for a plurality of diseases with abnormally high expression of ACLY, such as cancer, hyperlipidemia and arteriosclerotic cardiovascular diseases.

Methods of treating a subject having a metabolic syndrome or disease, diabetes, obesity, overweight, eating disorders, polyphagia, hyperlipidemia, insulin resistance, or methods of reducing body weight in a subject are provided. The methods involve administering to the subject a composition comprising a compound of formula I, including, for example, GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6- or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer, stereoisomer, tautomer or isotope variant thereof, and a pharmaceutically acceptable carrier or excipient.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to GLP-1 / GIP / GCG triple receptor agonists and their use in the treatment or prevention of type 2 diabetes (T2DM), hyperlipidemia / dyslipidemia, metabolic syndrome, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risk and / or obesity.

The application relates to the field of biological medicine, and particularly relates to application of kaempferol-3-O-acacia di-saccharide-7-O-rhamnose glycoside in preparation of a medicine for preventing and / or treating diseases related to glycolipid metabolism disorder. The compound or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof can be used for treating diseases such as type 2 diabetes, insulin resistance, hyperglycemia, hyperlipidemia and non-alcoholic fatty liver disease. The compound can significantly reduce intracellular glucose, triglyceride and total cholesterol levels, and can play a role by activating an AKT signal pathway, so as to improve glycolipid metabolism disorder and has potential clinical application value.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.

The present application relates to the field of microbial preparation, in particular to a probiotic composition beneficial to blood lipid health. The present application combines Bifidobacterium lactis MN-Gup, Bifidobacterium lactis M8, Lactobacillus plantarum LP6 and Lactobacillus casei PC01, and through animal experiment verification, can obviously reduce triglyceride and cholesterol in serum, and thus can be used for preventing and improving corresponding types of hyperlipidemia.

The invention relates to a heart failure risk prediction method and device, equipment and a medium. According to the method, clinical index data of a patient suffering from acute myocardial infarction are obtained, the clinical index data comprise the age, the diabetes disease condition, the hyperlipidemia disease condition, the renal insufficiency disease condition and the cerebral apoplexy disease condition, and an initial prediction model of the concurrent heart failure risk of the patient suffering from acute myocardial infarction is constructed; and obtaining an initial prediction model, training the initial prediction model to obtain a target prediction model, inputting the clinical index data into the target prediction model, and outputting a risk prediction value of the acute myocardial infarction patient concurrent with heart failure based on the target prediction model. By means of the method, conventional and easily-obtained clinical indexes can be used, it is not needed to wait for complex or expensive examination results, evaluation can be conducted immediately after a patient enters a hospital, subjective experience judgment is replaced with the model, quantitative risk values are output, and a basis is provided for clinical decision making.

The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The invention provides a diet guidance system and method for medical interaction of a hyperlipemia patient, and is applied to the technical field of medical data processing. The method comprises the following steps: firstly, collecting demographic, clinical index, medical history and risk factor data for a hyperlipemia patient, and constructing a training sample set; dividing risk levels by using a Python model based on a guide, and screening intervention crowds; according to consensus and guide, energy intake is customized according to BMI and physical labor intensity, a dietary structure is constructed and verified, and a personalized dietary scheme is generated; furthermore, VR education content is developed, and fat visualization is realized through 3D modeling, physical attribute configuration and a rendering scheme; meanwhile, standardizing 9 types of food materials by taking 5g of fat as a unit, converting intake exchange parts and calculating the total fat amount; and finally, the compliance of the patient is improved by means of a VR gamification module.

The utility model discloses a limb pressure sleeve capable of being used for cold and hot compress, which comprises a pressure sleeve body, an air pipe arranged in the pressure sleeve body, a plurality of air bags symmetrically arranged on one side face of the pressure sleeve body, a contact layer arranged on one side face of the pressure sleeve body, a heating film arranged between the contact layer and the pressure sleeve body, and a cable arranged in the pressure sleeve body. A plurality of notches are symmetrically formed in one side face of the contact layer, a storage bag is arranged on one side face of the contact layer and located among the notches, and a second hook-and-loop fastener thorn face is arranged on one side face of the inner wall of the storage bag. The heating film is heated through power supply of the cable, the heating film is a carbon nano tube / TPU composite film, the heating film is started to heat the legs, and heating can enable local blood vessels to expand, increase blood flow, improve the conveying efficiency of oxygen and nutrient substances, accelerate discharge of metabolic waste, reduce blood viscosity and reduce blood flow resistance, so that the legs are protected from being damaged. The pharmaceutical composition is of clinical significance to patients with hyperlipidemia or diabetes mellitus.